WooGene B&G Co., Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 14, 2023 at 11:41 am IST
Share
WooGene B&G Co., Ltd reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net income was KRW 615.56 million compared to net loss of KRW 99.47 million a year ago. Basic earnings per share from continuing operations was KRW 22 compared to basic loss per share from continuing operations of KRW 3 a year ago. Diluted earnings per share from continuing operations was KRW 22 compared to diluted loss per share from continuing operations of KRW 3 a year ago. Basic earnings per share was KRW 22 compared to basic loss per share of KRW 3 a year ago.
For the six months, sales was KRW 0.00001 million compared to KRW 0.00001 million a year ago. Net income was KRW 309.1 million compared to KRW 264.74 million a year ago. Basic earnings per share from continuing operations was KRW 11 compared to KRW 9 a year ago. Diluted earnings per share from continuing operations was KRW 11 compared to KRW 9 a year ago. Basic earnings per share was KRW 11 compared to KRW 9 a year ago.
WooGene B&G Co., Ltd. is a Korea-based company mainly engaged in the manufacture of veterinary drugs. The Companyâs products include anti-infective, bulk materials, probiotics, enzymes, antiparasitics, hormone preparations, vaccines, aquacultures, anesthetics, teat dips, disinfectants, pet cure drugs, calcium injections, antiphlogistic injections, enhance metabolism injections, diarrhea remedy injections, sedative injections for swine, toxin binders, pigmentation drugs and others. The Company also provides anti-inflammatory enzymes under the brand name SKD, which are used for human beings. The Company distributes its products within domestic market and to overseas markets, including Iran, Vietnam, Philippines, Brazil and others.
WOOGENE B&G CO., LTD 
